By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.




CEO: Ed Kaye, M.D.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT


Company News
Sarepta (SRPT) Announces Pricing Of $325 Million Public Offering Of Common Stock 7/25/2017 1:10:12 PM
Sarepta (SRPT) Announces Proposed $250 Million Public Offering Of Common Stock 7/24/2017 11:06:38 AM
Sarepta (SRPT) Secures $100 Million In Debt Financing 7/19/2017 11:15:38 AM
Clinigen And Sarepta (SRPT) Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 7/19/2017 7:48:15 AM
Sarepta (SRPT) And BioMarin (BMRN) Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation 7/18/2017 6:39:00 AM
New Sarepta (SRPT) CEO's M&A Experience Sparks Sale Speculation 6/30/2017 6:14:16 AM
Sarepta (SRPT) Taps Allergan (AGN) Alum as New CEO 6/29/2017 5:37:04 AM
Sarepta (SRPT) To Announce Second Quarter 2017 Financial Results And Recent Corporate Developments On July 19, 2017 6/28/2017 8:22:43 AM
Sarepta (SRPT) Announces Grand Opening Of Its Research And Manufacturing Center At Andover 6/27/2017 8:09:57 AM
Sarepta (SRPT) And Genethon Announce A Gene Therapy Research Collaboration For The Treatment Of Duchenne Muscular Dystrophy 6/21/2017 7:40:08 AM